Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target is $140.00. Charlie CY Yang has ...

The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Rumours that Merck was planning a $30 billion-plus takeover bid for Seagen have so far come to nothing, but it did complete a deal to buy VelosBio for $2.75 billion in late 2020 to add an ADC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analysts see big upside for these undervalued health care stocks.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

After hours: September 20 at 7:52 PM EDT ...